Detected ·
Beyang Therapeutics
$30M—
Beyang Therapeutics, a Shanghai-based AI drug discovery company, closed an oversubscribed Series A of nearly $30M co-led by Legend Capital and Shanghai Healthcare Capital. The company uses its ExCEED platform to design novel molecular scaffolds, with a pipeline including BT01002, a second-gen Menin inhibitor for acute leukemia.
- Website
- www.beyangtx.com
- Amount
- $30 000 000 USD
- Stage
- —
- Event
- Funding round
- Detected
- 2026-08-16 12:01:49 UTC
- Signal ID
- d4b12d61-76a2-4a0f-8244-68fc7bd6bdd9
As the API returns it
{
"id": "d4b12d61-76a2-4a0f-8244-68fc7bd6bdd9",
"created_at": "2026-08-16T12:01:49.451116Z",
"company_name": "Beyang Therapeutics",
"company_website_url": "www.beyangtx.com",
"company_linkedin_url": "https://www.linkedin.com/company/beyang-therapeutics",
"event_type": "funding",
"funding_amount": 30000000,
"funding_currency": "USD",
"funding_stage": null,
"message": "*Beyang Therapeutics, a Shanghai-based AI drug discovery company, closed an oversubscribed Series A of nearly $30M co-led by Legend Capital and Shanghai Healthcare Capital. The company uses its ExCEED platform to design novel molecular scaffolds, with a pipeline including BT01002, a second-gen Menin inhibitor for acute leukemia.*"
}